Should You Forget Pfizer and Buy This Pharma Stock Instead?

The article argues AbbVie is financially stronger than Pfizer, citing 2025 revenue growth of 8.6% to $61.2B versus Pfizer's 2% revenue decline to $62.6B. AbbVie's 2026 guidance is also much stronger, with revenue expected around $67B (+9.5%) and adjusted EPS of $14.37-$14.57 (+44.7% at the midpoint), while Pfizer guides for lower revenue and EPS. The comparison also highlights AbbVie's more sustainable dividend payout ratio of 65% versus Pfizer's 107% and AbbVie's stronger patent-cliff management.

Analysis

The market is pricing ABBV and PFE as simple dividend names, but the real divergence is pipeline quality and the shape of the next 24 months of cash conversion. ABBV’s immunology mix now has enough scale to behave like an annuity, which matters because it reduces the probability that any single LOE event creates a sudden multiple reset. PFE, by contrast, still looks like a post-pandemic reversion story: the company can defend cash flow for now, but it lacks a near-term catalyst stack that offsets the next wave of revenue attrition.

The second-order effect is that ABBV’s improving growth profile should compress its equity risk premium faster than its stated yield would suggest. Investors who screen only for dividend yield may continue to overlook that a safer 3% yield with double-digit forward EPS growth is mechanically more valuable than a 6% yield funded by a stretched payout ratio. In a higher-rate market, that distinction matters because the equity starts trading more like a quality-growth compounder than a bond proxy.

The key risk is timing: PFE does not need to break immediately to remain dangerous for shorts, because dividend support can keep the stock range-bound for months. But the setup worsens materially into the 2028 generic window on its key revenue contributor, so the asymmetry is negative on a 12- to 36-month horizon. For ABBV, the main risk is that the market has already discounted the transition and is now underestimating how much of 2026 guidance is already embedded; if that happens, the upside becomes more about multiple stability than outright rerating.

Contrarian read: consensus is still treating ABBV as a mature pharma with limited growth optionality, when in fact it has become one of the few large-cap healthcare names with visible operating leverage into 2026. The market may also be underappreciating that PFE’s strongest defense is capital return, not business momentum, which is a fragile thesis if execution disappoints even modestly.

Key Decisions for Investors

• Long ABBV / short PFE as a 6-12 month pair trade: prefer the name with visible 2026 EPS acceleration over the one with dividend-supported stagnation; target 10-15% relative outperformance if guidance holds.
• Buy ABBV on any 3-5% pullback over the next 2-4 weeks: risk/reward favors adding before the market fully reprices the 2026 growth inflection; downside is limited by cash flow durability.
• Avoid initiating fresh long PFE for income only unless you are explicitly willing to own a low-growth, high-payout story for 12+ months; the risk/reward is poor if the market starts to price dividend sustainability more skeptically.
• For income accounts, prefer ABBV calls against stock or covered-call overlays rather than chasing PFE yield: lower headline yield, but better probability-weighted total return over the next year.
• Monitor PFE into the next two earnings prints; if adjusted EPS guidance is revised lower again, consider shorting into strength or increasing the ABBV/PFE pair, as the stock is likely to de-rate before the dividend is forced into focus.